HEALTH
- Share via
Miles Inc. Reportedly Under Investigation: The Pittsburgh-based pharmaceutical company is being investigated for a now-halted program that paid pharmacists to steer patients to Adalat CC, Miles’ medication for high blood pressure, the Wall Street Journal reported this week. A federal anti-kickback law forbids any person or company from offering cash or in-kind payment to get business under Medicare or Medicaid, two federal health care programs. In a statement, Miles said it is involved in confidential talks with the government over the program, which it called “lawful and constructive.” Under the program, Miles paid drugstores $35 if a customer switched to its drug from Procardia Xl, sold by Pfizer Inc.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.